Porcelijn L, Folman C C, Bossers B, Huiskes E, Overbeeke M A, v d Schoot C E, de Haas M, von dem Borne A E
Central Laboratory of The Netherlands Red Cross Blood Transfusion Service, Amsterdam.
Thromb Haemost. 1998 Jun;79(6):1101-5.
It has been reported that blood trombopoietin (TPO) levels can discriminate between thrombocytopenia due to increased platelet destruction and decreased platelet production. With our TPO ELISA and a glycocalicin ELISA we analysed a large group of patients in detail and could confirm and amplify the above notion in detail. TPO levels were determined in plasma from 178 clinically and serologically well-defined thrombocytopenic patients: 72 patients with idiopathic autoimmune thrombocytopenia (AITP), 29 patients with secondary AITP, 5 patients with amegakaryocytic thrombocytopenia and 72 patients who suffered from various diseases (46 in whom megakaryocyte deficiency was not and 26 in whom it was expected). In addition, we measured the level of glycocalicin as a marker of total body mass of platelets. In all patients with primary AITP and secondary AITP, TPO levels were within the normal range or in some (n = 7) cases only slightly increased. The level of glycocalicin was not significantly different from that of the controls (n = 95). The patients with amegakaryocytic thrombocytopenia had strongly elevated TPO levels and significantly decreased glycocalicin levels. Similarly, among the 72 thrombocytopenic patients with various disorders, elevated TPO levels were only found in patients in whom platelet production was depressed. The mean level of glycocalicin in these patients was decreased compared to that in controls and patients with AITP, but was not as low as in patients with amegakaryocytic thrombocytopenia. In conclusion, all patients with depressed platelet production had elevated levels of circulating TPO, whereas the TPO levels in patients with an immune-mediated thrombocytopenia were mostly within the normal range. Therefore, measurement of plasma TPO levels provides valuable diagnostic information for the analysis of thrombocytopenia in general. Moreover, treatment with TPO may be an option in AITP.
据报道,血液中血小板生成素(TPO)水平可区分因血小板破坏增加所致的血小板减少症和血小板生成减少所致的血小板减少症。我们使用TPO酶联免疫吸附测定法(ELISA)和糖萼蛋白ELISA对一大组患者进行了详细分析,能够详细证实并扩展上述观点。对178例临床和血清学明确诊断的血小板减少症患者的血浆TPO水平进行了测定:72例特发性自身免疫性血小板减少症(AITP)患者、29例继发性AITP患者、5例无巨核细胞性血小板减少症患者以及72例患有各种疾病的患者(其中46例无巨核细胞缺乏,26例预期有巨核细胞缺乏)。此外,我们测定了糖萼蛋白水平作为血小板总体质量的标志物。在所有原发性AITP和继发性AITP患者中,TPO水平在正常范围内,或在某些(n = 7)病例中仅略有升高。糖萼蛋白水平与对照组(n = 95)无显著差异。无巨核细胞性血小板减少症患者的TPO水平大幅升高,糖萼蛋白水平显著降低。同样,在72例患有各种疾病的血小板减少症患者中,仅在血小板生成受抑制的患者中发现TPO水平升高。与对照组和AITP患者相比,这些患者的糖萼蛋白平均水平降低,但不像无巨核细胞性血小板减少症患者那样低。总之,所有血小板生成受抑制的患者循环TPO水平升高,而免疫介导性血小板减少症患者的TPO水平大多在正常范围内。因此,血浆TPO水平的测定为一般血小板减少症的分析提供了有价值的诊断信息。此外,TPO治疗可能是AITP的一种选择。